Misplaced Pages

Amdoxovir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Medication Pharmaceutical compound
Amdoxovir
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • methanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H12N6O3
Molar mass252.234 g·mol
3D model (JSmol)
SMILES
  • n2c1c(nc(nc1n(c2)3O(OC3)CO)N)N
InChI
  • InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1
  • Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N
  (verify)

Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma.

Amdoxovir was in advanced Phase II clinical trials around 2010. In 2013, a Phase II trial was terminated and another was withdrawn before it started. No further studies appear to have been done.

References

  1. "Amdoxovir". AIDSmeds.com. January 13, 2009. Archived from the original on 2008-03-21. Retrieved March 21, 2008.
  2. Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF (2010). "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther. 15 (2): 185–192. doi:10.3851/IMP1514. PMC 7733239. PMID 20386073.
  3. Clinical trial number NCT01737359 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
  4. Clinical trial number NCT01738555 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1 generation
2 generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1 generation
2 generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. Formerly or rarely used agent.
Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: